|
1
|
Blumberg BS: Hepatitis B: The hunt for a
killer vaccine. Princeton and Oxford: Princeton University Press,
2002.
|
|
2
|
Alter HJ and Blumberg BS: Further studies
on a ‘new’ human isoprecipitin system (Australia antigen). Blood.
27:297–309. 1966.PubMed/NCBI
|
|
3
|
Prince AM: Relation of Australia and SH
antigens. Lancet. 2:462–463. 1968.PubMed/NCBI View Article : Google Scholar
|
|
4
|
MacCallum FO: Early studies of viral
hepatitis. Br Med Bull. 28:105–108. 1972.PubMed/NCBI View Article : Google Scholar
|
|
5
|
MacCallum FO: Hepatitis. Am J Dis Child.
123:332–335. 1972.PubMed/NCBI View Article : Google Scholar
|
|
6
|
MacCallum FO: 1971 International symposium
on viral hepatitis. Historical perspectives. Can Med Assoc J.
106(Spec Issue): (Suppl):S423–S426. 1972.PubMed/NCBI
|
|
7
|
Dane DS, Cameron CH and Briggs M:
Virus-like particles in serum of patients with
Australia-antigen-associated hepatitis. Lancet. 1:695–698.
1970.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gerlich WH: Medical virology of hepatitis
B: How it began and where we are now. Virol J.
10(239)2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Krugman S, Giles JP and Hammond J: Viral
hepatitis, type B (MS-2 strain). Studies on active immunization.
JAMA. 217:41–45. 1971.PubMed/NCBI
|
|
10
|
Purcell RH and Gerin JL: Hepatitis B
subunit vaccine: A preliminary report of safety and efficacy tests
in chimpanzees. Am J Med Sci. 270:395–399. 1975.PubMed/NCBI
|
|
11
|
Hilleman MR, Buynak EB, Roehm RR, Tytell
AA, Bertland AU and Lampson GP: Purified and inactivated human
hepatitis B vaccine: Progress report. Am J Med Sci. 270:401–404.
1975.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Buynak EB, Roehm RR, Tytell AA, Bertland
AU II, Lampson GP and Hilleman MR: Development and chimpanzee
testing of a vaccine against human hepatitis B. Proc Soc Exp Biol
Med. 151:694–700. 1976.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Szmuness W, Stevens CE, Harley EJ, Zang
EA, Oleszko WR, William DC, Sadovsky R, Morrison JM and Kellner A:
Hepatitis B vaccine: Demonstration of efficacy in a controlled
clinical trial in a high-risk population in the United States. N
Engl J Med. 303:833–841. 1980.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Gerlich WH: Prophylactic vaccination
against hepatitis B: Achievements, challenges and perspectives. Med
Microbiol Immunol. 204:39–55. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chen DS, Hsu NH, Sung JL, Hsu TC, Hsu ST,
Kuo YT, Lo KJ and Shih YT: A mass vaccination program in Taiwan
against hepatitis B virus infection in infants of hepatitis B
surface antigen-carrier mothers. JAMA. 257:2597–2603.
1987.PubMed/NCBI
|
|
16
|
Whittle HC, Inskip H, Hall AJ, Mendy M,
Downes R and Hoare S: Vaccination against hepatitis B and
protection against chronic viral carriage in The Gambia. Lancet.
337:747–750. 1991.PubMed/NCBI View Article : Google Scholar
|
|
17
|
The Gambia Hepatitis Intervention Study
The Gambia Hepatitis Study Group. Cancer Res. 47:5782–5787.
1987.PubMed/NCBI
|
|
18
|
Shepard CW, Simard EP, Finelli L, Fiore AE
and Bell BP: Hepatitis B virus infection: Epidemiology and
vaccination. Epidemiol Rev. 28:112–125. 2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kane MA: Status of hepatitis B
immunization programmes in 1998. Vaccine. 16 (Suppl):S104–S108.
1998.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Komatsu H: Hepatitis B virus: Where do we
stand and what is the next step for eradication? World J
Gastroenterol. 20:8998–9016. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Pasek M, Goto T, Gilbert W, Zink B,
Schaller H, MacKay P, Leadbetter G and Murray K: Hepatitis B virus
genes and their expression in E. coli. Nature. 282:575–579.
1979.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Valenzuela P, Gray P, Quiroga M, Zaldivar
J, Goodman HM and Rutter WJ: Nucleotide sequence of the gene coding
for the major protein of hepatitis B virus surface antigen. Nature.
280:815–819. 1979.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Charnay P, Pourcel C, Louise A, Fritsch A
and Tiollais P: Cloning in Escherichia coli and physical structure
of hepatitis B virion DNA. Proc Natl Acad Sci USA. 76:2222–2226.
1979.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Valenzuela P, Medina A, Rutter WJ, Ammerer
G and Hall BD: Synthesis and assembly of hepatitis B virus surface
antigen particles in yeast. Nature. 298:347–350. 1982.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Harford N, Cabezon T, Crabeel M, Simoen E,
Rutgers A and De Wilde M: Expression of hepatitis B surface antigen
in yeast. Dev Biol Stand. 54:125–130. 1983.PubMed/NCBI
|
|
26
|
Poovorawan Y, Sanpavat S, Pongpunlert W,
Chumdermpadetsuk S, Sentrakul P and Safary A: Protective efficacy
of a recombinant DNA hepatitis B vaccine in neonates of HBe
antigen-positive mothers. JAMA. 261:3278–3281. 1989.PubMed/NCBI
|
|
27
|
McGregor A: WHO: World Health Assembly.
Lancet. 339(1287)1992.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zanetti AR, Van Damme P and Shouval D: The
global impact of vaccination against hepatitis B: A historical
overview. Vaccine. 26:6266–6273. 2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Gerlich WH, Glebe D, Kramvis A and Magnius
LO: Peculiarities in the designations of hepatitis B virus genes,
their products, and their antigenic specificities: A potential
source of misunderstandings. Virus Genes. 56:109–119.
2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
World Health Organization (WHO):
Immunization Coverage. WHO, Geneva, 2023. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage.
Accessed Oct 10, 2022.
|
|
31
|
World Health Organization (WHO): Interim
guidance for country validation of viral hepatitis elimination.
WHO, Geneva, 2021. Accessed Oct 10, 2022.
|
|
32
|
Goldstein ST, Zhou F, Hadler SC, Bell BP,
Mast EE and Margolis HS: A mathematical model to estimate global
hepatitis B disease burden and vaccination impact. Int J Epidemiol.
34:1329–1339. 2005.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Nayagam S, Thursz M, Sicuri E, Conteh L,
Wiktor S, Low-Beer D and Hallett TB: Requirements for global
elimination of hepatitis B: a modelling study. Lancet Infect Dis.
16:1399–1408. 2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Hoofnagle JH, Doo E, Liang TJ, Fleischer R
and Lok AS: Management of hepatitis B: Summary of a clinical
research workshop. Hepatology. 45:1056–1075. 2007.PubMed/NCBI View Article : Google Scholar
|
|
35
|
McMahon BJ: The natural history of chronic
hepatitis B virus infection. Semin Liver Dis. 24 (Suppl 1):S17–S21.
2004.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Marion SA, Tomm Pastore M, Pi DW and
Mathias RG: Long-term follow-up of hepatitis B vaccine in infants
of carrier mothers. Am J Epidemiol. 140:734–746. 1994.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Hepatitis B vaccines: WHO position paper -
July 2017. Wkly Epidemiol Rec. 92:369–392. 2017.PubMed/NCBI(In English, French).
|
|
38
|
Are booster immunisations needed for
lifelong hepatitis B immunity? European Consensus Group on
Hepatitis B Immunity. Lancet. 355:561–565. 2000.PubMed/NCBI
|
|
39
|
Niu MT, Rhodes P, Salive M, Lively T,
Davis DM, Black S, Shinefield H, Chen RT and Ellenberg SS:
Comparative safety of two recombinant hepatitis B vaccines in
children: Data from the Vaccine Adverse Event Reporting System
(VAERS) and Vaccine Safety Datalink (VSD). J Clin Epidemiol.
51:503–510. 1998.PubMed/NCBI View Article : Google Scholar
|
|
40
|
McMahon BJ, Helminiak C, Wainwright RB,
Bulkow L, Trimble BA and Wainwright K: Frequency of adverse
reactions to hepatitis B vaccine in 43,618 persons. Am J Med.
92:254–256. 1992.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Lewis E, Shinefield HR, Woodruff BA, Black
SB, Destefano F, Chen RT and Ensor R: Vaccine Safety Datalink
Workgroup. Safety of neonatal hepatitis B vaccine administration.
Pediatr Infect Dis J. 20:1049–1054. 2001.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Liu Y, Zhang M, Yang M and Chen Q: Adverse
Events of Vaccination against Hepatitis B Virus in Post-Marketing
Surveillance from 2005 to 2017 in Guangdong Province, China.
Vaccines (Basel). 10(1087)2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Niu MT, Salive ME and Ellenberg SS:
Neonatal deaths after hepatitis B vaccine: The vaccine adverse
event reporting system, 1991-1998. Arch Pediatr Adolesc Med.
153:1279–1282. 1999.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Eriksen EM, Perlman JA, Miller A, Marcy
SM, Lee H, Vadheim C, Zangwill KM, Chen RT, DeStefano F, Lewis E,
et al: Lack of association between hepatitis B birth immunization
and neonatal death: A population-based study from the vaccine
safety datalink project. Pediatr Infect Dis J. 23:656–662.
2004.PubMed/NCBI View Article : Google Scholar
|
|
45
|
DeStefano F, Mullooly JP, Okoro CA, Chen
RT, Marcy SM, Ward JI, Vadheim CM, Black SB, Shinefield HR, Davis
RL, et al: Childhood vaccinations, vaccination timing, and risk of
type 1 diabetes mellitus. Pediatrics. 108(E112)2001.PubMed/NCBI View Article : Google Scholar
|
|
46
|
DeStefano F, Verstraeten T, Jackson LA,
Okoro CA, Benson P, Black SB, Shinefield HR, Mullooly JP, Likosky
W, Chen RT, et al: Vaccinations and risk of central nervous system
demyelinating diseases in adults. Arch Neurol. 60:504–509.
2003.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Duclos P: Safety of immunisation and
adverse events following vaccination against hepatitis B. Expert
Opin Drug Saf. 2:225–231. 2003.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Hernan MA, Jick SS, Olek MJ and Jick H:
Recombinant hepatitis B vaccine and the risk of multiple sclerosis:
A prospective study. Neurology. 63:838–842. 2004.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Sestili C, Grazina I and La Torre G: HBV
vaccine and risk of developing multiple sclerosis: A systematic
review and meta-analysis. Hum Vaccin Immunother. 17:2273–2278.
2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Schillie S, Vellozzi C, Reingold A, Harris
A, Haber P, Ward JW and Nelson NP: Prevention of Hepatitis B Virus
Infection in the United States: Recommendations of the Advisory
Committee on Immunization Practices. MMWR Recomm Rep. 67:1–31.
2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Obando-Pacheco P, Rivero-Calle I,
Gómez-Rial J, Rodríguez-Tenreiro Sánchez C and Martinón-Torres F:
New perspectives for hexavalent vaccines. Vaccine. 36:5485–5494.
2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Maman K, Zöllner Y, Greco D, Duru G,
Sendyona S and Remy V: The value of childhood combination vaccines:
From beliefs to evidence. Hum Vaccin Immunother. 11:2132–2141.
2015.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Jack AD, Hall AJ, Maine N, Mendy M and
Whittle HC: What level of hepatitis B antibody is protective? J
Infect Dis. 179:489–492. 1999.PubMed/NCBI View
Article : Google Scholar
|
|
54
|
Dentinger CM, McMahon BJ, Butler JC,
Dunaway CE, Zanis CL, Bulkow LR, Bruden DL, Nainan OV, Khristova
ML, Hennessy TW and Parkinson AJ: Persistence of antibody to
hepatitis B and protection from disease among Alaska natives
immunized at birth. Pediatr Infect Dis J. 24:786–792.
2005.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Hammitt LL, Hennessy TW, Fiore AE, Zanis
C, Hummel KB, Dunaway E, Bulkow L and McMahon BJ: Hepatitis B
immunity in children vaccinated with recombinant hepatitis B
vaccine beginning at birth: A follow-up study at 15 years. Vaccine.
25:6958–6964. 2007.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Samandari T, Fiore AE, Negus S, Williams
JL, Kuhnert W, McMahon BJ and Bell BP: Differences in response to a
hepatitis B vaccine booster dose among Alaskan children and
adolescents vaccinated during infancy. Pediatrics. 120:e373–e381.
2007.PubMed/NCBI View Article : Google Scholar
|
|
57
|
McMahon BJ, Dentinger CM, Bruden D, Zanis
C, Peters H, Hurlburt D, Bulkow L, Fiore AE, Bell BP and Hennessy
TW: Antibody levels and protection after hepatitis B vaccine:
Results of a 22-year follow-up study and response to a booster
dose. J Infect Dis. 200:1390–1396. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
58
|
Funderburke PL and Spencer L: Hepatitis B
immunity in high risk health care workers. Seven years post
vaccination. AAOHN J. 48:325–330. 2000.PubMed/NCBI
|
|
59
|
McMahon BJ, Bruden DL, Petersen KM, Bulkow
LR, Parkinson AJ, Nainan O, Khristova M, Zanis C, Peters H and
Margolis HS: Antibody levels and protection after hepatitis B
vaccination: Results of a 15-year follow-up. Ann Intern Med.
142:333–341. 2005.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Spradling PR, Williams RE, Xing J, Soyemi
K and Towers J: Serologic testing for protection against hepatitis
B virus infection among students at a health sciences university in
the United States. Infect Control Hosp Epidemiol. 33:732–736.
2012.PubMed/NCBI View
Article : Google Scholar
|
|
61
|
Stevens CE, Toy PT, Taylor PE, Lee T and
Yip HY: Prospects for control of hepatitis B virus infection:
Implications of childhood vaccination and long-term protection.
Pediatrics. 90 (1 Pt 2):170–173. 1992.PubMed/NCBI
|
|
62
|
Watson B, West DJ, Chilkatowsky A, Piercy
S and Ioli VA: Persistence of immunologic memory for 13 years in
recipients of a recombinant hepatitis B vaccine. Vaccine.
19:3164–3168. 2001.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Williams JL, Christensen CJ, McMahon BJ,
Bulkow LR, Cagle HH, Mayers JS, Zanis CL, Parkinson AJ and Margolis
HS: Evaluation of the response to a booster dose of hepatitis B
vaccine in previously immunized healthcare workers. Vaccine.
19:4081–4085. 2001.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Bruce MG, Bruden D, Hurlburt D, Zanis C,
Thompson G, Rea L, Toomey M, Townshend-Bulson L, Rudolph K, Bulkow
L, et al: Antibody Levels and Protection After Hepatitis B Vaccine:
Results of a 30-Year Follow-up Study and Response to a Booster
Dose. J Infect Dis. 214:16–22. 2016.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Simons BC, Spradling PR, Bruden DJ, Zanis
C, Case S, Choromanski TL, Apodaca M, Brogdon HD, Dwyer G, Snowball
M, et al: A Longitudinal Hepatitis B vaccine cohort demonstrates
long-lasting hepatitis B Virus (HBV) cellular immunity despite loss
of antibody against HBV surface antigen. J Infect Dis. 214:273–280.
2016.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Leuridan E and Van Damme P: Hepatitis B
and the need for a booster dose. Clin Infect Dis. 53:68–75.
2011.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Stramer SL, Wend U, Candotti D, Foster GA,
Hollinger FB, Dodd RY, Allain JP and Gerlich W: Nucleic acid
testing to detect HBV infection in blood donors. N Engl J Med,.
364:236–247. 2011.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Tosti ME, Alfonsi V, Lacorte E, Mele A,
Galli C, Zanetti AR and Romanò L: SEIEVA Collaborating Group. Acute
Hepatitis B After the Implementation of Universal Vaccination in
Italy: Results from 22 years of surveillance (1993-2014). Clin
Infect Dis. 62:1412–1418. 2016.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Beasley RP, Hwang LY, Stevens CE, Lin CC,
Hsieh FJ, Wang KY, Sun TS and Szmuness W: Efficacy of hepatitis B
immune globulin for prevention of perinatal transmission of the
hepatitis B virus carrier state: Final report of a randomized
double-blind, placebo-controlled trial. Hepatology. 3:135–141.
1983.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Lee C, Gong Y, Brok J, Boxall EH and Gluud
C: Hepatitis B immunisation for newborn infants of hepatitis B
surface antigen-positive mothers. Cochrane Database Syst Rev.
(2)(CD004790)2006.PubMed/NCBI View Article : Google Scholar
|
|
71
|
World Health Organization (WHO):
Guidelines for the prevention, care and treatment of persons with
chronic hepatitis B infection. WHO, Geneva, 2015. https://apps.who.int/iris/handle/10665/154590.
Accessed Oct 10, 2022.
|
|
72
|
Viral Hepatitis Prevention Board (VHPB):
Prevention and control of hepatitis B with combined vaccines and
timely birth dose vaccination: Hanoi, Vietnam. VHPB, Belgium, 2018.
Accessed Oct 10, 2022.
|
|
73
|
Kramvis A: Challenges for hepatitis B
virus cure in resource-limited settings in sub-Saharan Africa. Curr
Opin HIV AIDS. 15:185–192. 2020.PubMed/NCBI View Article : Google Scholar
|
|
74
|
World Health Organization (WHO): Hepatitis
B vaccination coverage. WHO, Geneva, 2023. Accessed Oct 10,
2022.
|
|
75
|
Spearman CW, Sonderup MW, Botha JF, van
der Merwe SW, Song E, Kassianides C, Newton KA and Hairwadzi HN:
Division of Hepatology, Department of Medicine, University of Cape
Town, South Africa. South African guideline for the management of
chronic hepatitis B: 2013. S Afr Med J. 103 (5 Pt 2):337–349.
2013.PubMed/NCBI
|
|
76
|
Amponsah-Dacosta E, Lebelo RL, Rakgole JN,
Burnett RJ, Selabe SG and Mphahlele MJ: Evidence for a change in
the epidemiology of hepatitis B virus infection after nearly two
decades of universal hepatitis B vaccination in South Africa. J Med
Virol. 86:918–924. 2014.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Tsebe KV, Burnett RJ, Hlungwani NP, Sibara
MM, Venter PA and Mphahlele MJ: The first five years of universal
hepatitis B vaccination in South Africa: Evidence for elimination
of HBsAg carriage in under 5-year-olds. Vaccine. 19:3919–3926.
2001.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Burnett RJ, Kramvis A, Dochez C and Meheus
A: An update after 16 years of hepatitis B vaccination in South
Africa. Vaccine. 30 (Suppl 3):C45–C51. 2012.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Maepa MB, Ely A, Kramvis A, Bloom K,
Naidoo K, Simani OE, Maponga TG and Arbuthnot P: Hepatitis B Virus
Research in South Africa. Viruses. 14(1939)2022.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Chang MH: Decreasing incidence of
hepatocellular carcinoma among children following universal
hepatitis B immunization. Liver Int. 23:309–314. 2003.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Chang MH, You SL, Chen CJ, Liu CJ, Lee CM,
Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, et al: Decreased incidence
of hepatocellular carcinoma in hepatitis B vaccinees: A 20-year
follow-up study. J Natl Cancer Inst. 101:1348–1355. 2009.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Chang MH, Chen TH, Hsu HM, Wu TC, Kong MS,
Liang DC, Ni YH, Chen CJ and Chen DS: Taiwan Childhood HCC Study
Group. Prevention of hepatocellular carcinoma by universal
vaccination against hepatitis B virus: The effect and problems.
Clin Cancer Res. 11:7953–7957. 2005.PubMed/NCBI View Article : Google Scholar
|
|
83
|
McMahon BJ, Bulkow LR, Singleton RJ,
Williams J, Snowball M, Homan C and Parkinson AJ: Elimination of
hepatocellular carcinoma and acute hepatitis B in children 25 years
after a hepatitis B newborn and catch-up immunization program.
Hepatology. 54:801–807. 2011.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Prozesky OW, Szmuness W, Stevens CE, Kew
MC, Harley EJ, Hoyland JA, Scholtz JE, Mitchell AD, Shabangu A,
Kunene E, et al: Baseline epidemiological studies for a hepatitis B
vaccine trial in Kangwane. S Afr Med J. 64:891–893. 1983.PubMed/NCBI
|
|
85
|
Prozesky OW, Stevens CE, Szmuness W, Rolka
H, Harley EJ, Kew MC, Scholtz JE and Mitchell AD: Immune response
to hepatitis B vaccine in newborns. J Infect. 7 (Suppl 1):S53–S55.
1983.PubMed/NCBI View Article : Google Scholar
|
|
86
|
World Health Organization (WHO): Maternal,
Newborn, Child and Adolescent Health and Ageing: Data Portal. WHO,
Geneva, 2023. Accessed Oct 10, 2022.
|
|
87
|
World Health Organization (WHO): Global
Hepatitis Report 2017. WHO, Geneva, 2023. Accessed Oct 10,
2022.
|
